Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Ipsen announces changes to its Executive Committee

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication